| A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2148 | 2003 |
| Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ... New England Journal of Medicine 369 (25), 2391-2405, 2013 | 2118 | 2013 |
| Clinical and biological implications of driver mutations in myelodysplastic syndromes E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ... Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013 | 1983 | 2013 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 1660 | 2022 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1528 | 2006 |
| Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ... New England Journal of Medicine 365 (15), 1384-1395, 2011 | 1420 | 2011 |
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders T Ernst, AJ Chase, J Score, CE Hidalgo-Curtis, C Bryant, AV Jones, ... Nature genetics 42 (8), 722-726, 2010 | 1351 | 2010 |
| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy A Hochhaus, S Kreil, AS Corbin, P La Rosee, MC Müller, T Lahaye, ... Leukemia 16 (11), 2190-2196, 2002 | 1228 | 2002 |
| Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders AV Jones, S Kreil, K Zoi, K Waghorn, C Curtis, L Zhang, J Score, R Seear, ... Blood 106 (6), 2162-2168, 2005 | 1165 | 2005 |
| Mutations and prognosis in primary myelofibrosis AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ... Leukemia 27 (9), 1861-1869, 2013 | 866 | 2013 |
| Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta JF Apperley, M Gardembas, JV Melo, R Russell-Jones, BJ Bain, EJ Baxter, ... New England Journal of Medicine 347 (7), 481-487, 2002 | 772 | 2002 |
| BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European … S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ... Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011 | 725 | 2011 |
| Aberrations of EZH2 in Cancer A Chase, NCP Cross Clinical cancer research 17 (9), 2613-2618, 2011 | 659 | 2011 |
| Prognostic score including gene mutations in chronic myelomonocytic leukemia R Itzykson, O Kosmider, A Renneville, V Gelsi-Boyer, M Meggendorfer, ... Journal of clinical oncology 31 (19), 2428-2436, 2013 | 575 | 2013 |
| Standardized definitions of molecular response in chronic myeloid leukemia NCP Cross, HE White, MC Müller, G Saglio, A Hochhaus Leukemia 26 (10), 2172-2175, 2012 | 481 | 2012 |
| JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms AV Jones, A Chase, RT Silver, D Oscier, K Zoi, YL Wang, H Cario, ... Nature genetics 41 (4), 446-449, 2009 | 473 | 2009 |
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient … S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, DW Kim, ... Blood, The Journal of the American Society of Hematology 112 (8), 3330-3338, 2008 | 466 | 2008 |
| Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation NC Cross, L Feng, A Chase, J Bungey, TP Hughes, JM Goldman | 461 | 1993 |
| Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms FH Grand, CE Hidalgo-Curtis, T Ernst, K Zoi, C Zoi, C McGuire, S Kreil, ... Blood, The Journal of the American Society of Hematology 113 (24), 6182-6192, 2009 | 451 | 2009 |
| CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy A Pardanani, RP Ketterling, SR Brockman, HC Flynn, SF Paternoster, ... Blood 102 (9), 3093-3096, 2003 | 444 | 2003 |
